| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| KRYSTAL-10 | 21-06 | Advanced Colorectal Cancer with KRAS G12C mutation with disease progression on or after standard first line therapy |
To compare the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation. |
DSSG Group: Gastrointestinal
HERIZON-GEA-01 (ZWI-ZW25-301) Zymeworks
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| HERIZON-GEA-01 (ZWI-ZW25-301) Zymeworks | 21-35 | The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic) |
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. |
LEAP-015 (MK-7902-015)
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| LEAP-015 (MK-7902-015) | 21-34 | Previously untreated advanced/ metastatic HER-2 negative gastric/ gasto-esophageal junction (GEJ) cancer. |
The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. |
DESTINY DS8201-A-U306
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| DESTINY DS8201-A-U306 | 21-07 | HER-2 positive metastatic and/or unresectable gastric or gasto-esophageal junction (GEJ) cancer |
This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd), a HER-2 targeting antinbody drug, compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) cancer who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy. |
Astellas 8951-CL-5201
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Astellas 8951-CL-5201 | CTRIAL-IE 18-44 | Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma |
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM, and health-related quality of life (HRQoL). |